Embed
Email

Evidence

Document Sample
Evidence
Shared by: HC11112907480
Categories
Tags
Stats
views:
1
posted:
11/29/2011
language:
English
pages:
29
Table 1: Detailed Description of Empirical Articles



# Article Objectives Study Design Main Findings Discussion

7 Lenze et al. To describe and assess:  Study type: Cross-sectional.  70 of the 182 subjects were taking at Compared to other studies, the

 Current and lifetime  Setting: Primary care and psychiatric least one psychotropic medication: BZs results of this study found a relative

“Comorbid anxiety rates and associated settings. (37 subjects). high rate of current and lifetime

disorders in clinical features of  Study Population:  35% of subjects with depressive anxiety disorders in elderly

depressed elderly anxiety disorders in  Size: N = 182. disorders had at least one lifetime depressed individuals. Comorbid

patients” depressed elderly  60 years and older. anxiety disorder diagnosis. anxiety disorders and symptoms of

patients.  23.1% Male.  23% had a current diagnosis. generalized anxiety disorder were

American Journal of  Most common current comorbid associated with a more severe

Psychiatry  Assessments included: 17-item anxiety disorders were panic disorder presentation of depressive illness

Hamilton Depression Rating Scale, (9.3%), specific phobias (8.8%), and in elderly subjects.

2000;157:722-728. the Global Assessment Scale (GAS), social phobia (6.6%).

the Medical Outcomes Study 36-item  Symptoms that met inclusion criteria Limitations included:

Short-Form Health Survey, the for generalized anxiety disorder,  A rate for diagnosis of

Cumulative Illness Rating Scale- measured separately, were present in generalized anxiety disorder

Geriatrics, the UKU Side Effect 27.5% of depressed subjects. was not available.

Rating Scale.  Presence of comorbid anxiety disorder  Cross-sectional design cannot

was associated with poorer social address the effects of

NOTE: This study was not performed function (p = 0.01) and a higher level of comorbid anxiety disorders on

in a long-term care setting. somatic symptoms (p = 0.02). outcomes of depression.

 Symptoms of generalized anxiety  Study was not performed in a

disorder were associated with a higher long-term care setting.

level of suicidality (p

American Geriatric short-acting agents.  Study population: 8 mg. These findings underscore

Society  Size: N = 2510.  For cohort members beginning an recommendations to use BZs very

 Mean age 83 years. episode of BZ use during follow-up, the cautiously in frail older patients,

2000;48:682-685.  75% were female. rate of falls was greatest in the 7 days and countermeasures to prevent

after the BZ was started, but remained falls should be taken.

 Outcome measures were falls during elevated by 30% after the first 30 days

study follow-up. of therapy. Limitations included:

 Short-acting drugs were those that  The rate of falls increased with BZ  Generalizability of study

had a half-life 28 day use (80% increase in may have limited the

risk). generalizability of the results.

 Study was not performed in a

long-term care setting.









19

Table 1: Detailed Description of Empirical Articles



# Article Objectives Study Design Main Findings Discussion

30 McAndrews et al. To describe and assess:  Study type: Prospective, controlled  After controlling for differences in There may be subtle and reversible

 Whether cognitive trial. affective status between BZ-users and effects of long-term BZ use on

“Cognitive effects of dysfunction and its  Setting: Sleep Disorders Clinic at the controls, there were no significant speed-dependent tasks in older

long-term reversal following BZ Toronto Western Hospital. group differences in cognitive adults. However, the magnitude of

benzodiazepine use discontinuation could  Study population: performance. these effects is quite small and

in older adults” be documented in  Size: N = 51, with N = 25 subjects  BZ-users showed greater gains on may be of little clinical significance

community-dwelling and N = 26 controls. tests of attention and speed of in the healthy elderly.

Human older adults.  47.1% Female. processing at repeat testing compared

Psychopharmacology:  Aged 50 and older. with controls. The authors commented that their

Clinical and  History of BZ use for more than 6 findings may conflict with other

Experimental months studies.



2003;18:51-57. NOTE: This study was not performed Limitations included:

in a long-term care setting.  High dropout rate.

 Generalizability of study

findings.

 Study was not performed in a

long-term care setting.









20

Table 1: Detailed Description of Empirical Articles



# Article Objectives Study Design Main Findings Discussion

31 Paterniti et al. To describe and assess:  Study type: Longitudinal.  Study participants were classified as Chronic use of BZs is a risk factor

 Whether chronic use of  Setting: Volunteers in the nonusers (67%), episodic (10%), for increased cognitive decline in

“Long-term BZs over a 4-year Epidemiology of Vascular Aging recurrent (6%), and chronic (7%). the elderly. These findings showed

benzodiazapine use period was associated (EVA) Study in Nantes, France  Recurrent and chronic BZ use was that chronic or recurrent use of BZs

and cognitive decline with an increased risk  Time period: Baseline data were associated with lower MMSE (Mini- had an apparent deleterious effect

in the elderly: The of cognitive decline. collected between June 1991 and Mental State Examination), DSS (Digit upon several cognitive functions.

Epidemiology of June 1993. Two follow-up Symbol Substitution Test), and TMT-B People who reported taking BZs at

Vascular Aging examinations were conducted 2 and (Trail Making Test, part B) scores only one of the three examinations

Study” 4 years after baseline. compared with nonuse. did not differ from nonusers.

 Study population:  Chronic use was also associated

Journal of Clinical  Size: N = 1176. with a lower FTT (Finger Tapping Limitations included:

Psychopharmacology  Age 60-70 years. Test) score.  Not having information on the

 Episodic BZ use did not alter dose or half-life at baseline and

2002;22:285-293.  Nonusers = those who did not report cognitive and psychomotor at the 4-year follow-up.

taking BZs at any of the three performances.  Subjects were classified on the

examinations  Over the 4-year period, episodic or basis of current use of drugs.

 Chronic users = those who reported recurrent use of BZs was not a  No objective measure of BZ

use of BZs at all three examinations significant risk factor for cognitive and exposure such as plasma

 Recurrent users = those who psychomotor decline. level.

reported use at two examinations  Chronic users had a significantly  No knowledge about the delay

 Episodic users = those who reported higher risk of cognitive decline for between last intake on BZs

use at one examination the MMSE, DSS, and TMT-B and cognitive testing.

compared to nonusers.  Having no information about

NOTE: This study was not performed  Results were independent of age, sex, psychiatric diagnosis and

in a long-term care setting. education, alcohol and tobacco use, history.

anxiety and depression scores, and  Study does not permit

use of psychotropic drugs other than conclusions about a causal

BZs. effect of BZs on cognitive

decline.

 Study was not performed in a

long-term care setting.









21

Table 1: Detailed Description of Empirical Articles



# Article Objectives Study Design Main Findings Discussion

32 Cohen-Mansfield et To describe and assess:  Study type: Random, placebo-  35 (60.3%) of 58 patients completed Long-term use of haloperidol,

al.  The effects of controlled, double-blind crossover the study. thioridazine, and lorazepam in

discontinuing treatment study.  For the primary outcomes, all analytic nursing homes to manage agitation

“Withdrawal of with haloperidol,  Setting: 550-bed skilled, nonprofit approaches resulted in non-significant should be closely monitored for

haloperidol, thioridazine, and nursing facility. differences for all variables and no their efficacy.

thioridazine, and lorazepam among  Study population: consistent trends were observed.

lorazepam in the residents of a large  Size: N = 58.  Comparison of the variables assessing Routine attempts at drug

nursing home” suburban nursing  74.1% Female. functioning, adverse effects, and global withdrawal should be considered

home.  Mean age 86 years. impression all resulted in non- for most residents taking

Archives of Internal significant differences between drug psychotropic medication.

Medicine  Half of the residents continued to and placebo.

take the psychotropic medication  The medications were effective in

1999;159(15):1733- they had been prescribed, whereas controlling verbal agitation during the Limitations included:

1740. the other half were tapered to evening (p = 0.03) and cognitive  Small sample size.

placebo. functioning improved during the taking

 After 6 weeks of taking placebo or of placebo compared with the taking of

original drug, patients were tapered a drug (p = 0.05).

to the reverse schedule and

remained on it for 6 weeks.

 Primary assessments included

informant ratings by the nursing staff

who completed the Brief Psychiatric

Rating Scale and the Cohen-

Mansfield Agitation Inventory.









22

Table 1: Detailed Description of Empirical Articles



# Article Objectives Study Design Main Findings Discussion

33 Salzman et al. To describe and assess:  Study type: Prospective, single blind,  Measures of memory and cognitive BZ-related cognitive impairment is

 Cognitive, affective, controlled trial functioning improved significantly after reversible. The residents

“Cognitive behavioral, and sleep  Setting: Nursing home. discontinuation of BZs. significantly improved in memory

improvement function after  Study population:  There was no associated increase in and cognitive functioning in

following discontinuation of BZs.  Size: N = 25. anxiety, agitation, or sleeplessness. comparison with residents who

benzodiazepine  Mean age 86 years.  60% of the subjects who had continued taking BZs.

discontinuation in discontinued use of BZs remained off

elderly nursing home  Results of 12 subjects assessed them 1 year later. Limitations included:

residents” before and after discontinuation of  Generalizability of results.

BZs were compared with those of 13

International Journal subjects who had not discontinued

of Geriatric Psychiatry BZ use.



1992;7:89-93.

34 Campbell et al. To describe and assess:  Study type: Randomized controlled  After 44 weeks, the relative hazard for Withdrawal of psychotropic

 The effectiveness of trial with a two by two factorial falls in the medication withdrawal medication significantly reduced

“Psychotropic psychotropic design. group compared with the group taking the risk of falling, but permanent

medication withdrawal medication withdrawal  Setting: 17 general practices in their original medication was 0.34. withdrawal is very difficult to

and a home-based and a home-based Dunedin, New Zealand.  The risk of falling for the exercise achieve.

exercise program to exercise program in  Study population: program group compared with those

prevent falls: A reducing falls in older  Size: N = 93. not receiving the exercise program was The authors recommended a larger

randomized controlled people.  Mean age 74.6 years. not significantly reduced. study to confirm these findings.

trial”  76.3% Female.  One month after completion of the

study, 47% of the participants from the Limitations included:

Journal of the  Two interventions: 1) gradual medication withdrawal group who had  Small sample size.

American Geriatrics withdrawal of psychotropic taken capsules containing placebo for  Study was not performed in a

Society medication versus continuing to take the final 30 weeks of the trial had long-term care setting.

psychotropic medication (double restarted taking psychotropic

1999;47(7):850-853. blind) and 2) a home-based exercise medication.

program versus no exercise program

(single blind).



NOTE: This study was not performed

in a long-term care setting.









23

Table 1: Detailed Description of Empirical Articles



# Article Objectives Study Design Main Findings Discussion

35 Petrovic et al. To describe and assess:  Study type: Prospective, single-blind  Overall success rate was 77.6% in the The authors comment that

 The hypothesis that a trial. group of volunteers and 67.9% in the stepwise BZ withdrawal is

“A programme for short-term program for  Setting: Inpatient geriatric ward of total group of eligible patients. surprisingly well tolerated in elderly

short-term withdrawal withdrawal of BZs is University Hospital, Ghent, Belgium.  No major withdrawal symptoms subjects.

from benzodiazepines feasible in hospitalized  Study population: occurred.

in geriatric hospital geriatric patients.  Size: N = 49.  The subjective quality of sleep Two-thirds of all eligible subjects

inpatients: Success  73% Female. (measured using the Groningen Sleep were still free of BZ use 6 weeks

rate and effect on  Mean age was 81.7 for Males and Quality scale) remained virtually after the start of the withdrawal

subjective sleep 81.2 for Females. unchanged in the course of the program. Deterioration of sleep

quality” program. quality or major withdrawal

NOTE: This study was not performed  Sleep quality was not significantly symptoms were not observed.

International Journal in a long-term care setting. different in patients on trazodone vs.

of Geriatric Psychiatry patients on lormetazepam. Limitations included:

 The success rate was similar in both  Lack of a placebo arm to the

1999;14(9):754-760. drug substitution groups. trial.

 Cannot predict the durability of

the withdrawal course in the

long term.

 Study was not performed in a

long-term care setting.









24

Table 1: Detailed Description of Empirical Articles



# Article Objectives Study Design Main Findings Discussion

36 Petrovic et al. To describe and assess:  Study type: Randomized, double-  The success rate was higher in the Initial replacement therapy with a

 The success of abrupt blind, placebo-controlled trial. lormetazepam substitution group (80% low-dose BZ is preferred over

“Fast withdrawal from cessation of BZ  Setting: Inpatient geriatric ward of vs. 50% in the placebo group, p < placebo, since the latter alternative

benzodiazepines in treatment in the University Hospital, Ghent, Belgium. 0.05). is associated with worse sleep

geriatric inpatients: A elderly, comparing the  Study population:  Both the subjective quality of sleep and quality and a lower success rate.

randomised double- effects of placebo with  Size: N = 40. withdrawal symptoms were Placebo must only be used under

blind, placebo- those of  Inpatients had been taking BZs for significantly better in the lormatazepam medical scrutiny, given the

controlled trial” lormetazepam, at least 3 months. substitution group. potential for unmasking delirious

defining withdrawal  Important withdrawal effects were symptoms, especially in patients

European Journal of success rate, sleep NOTE: This study was not performed observed in the control group in two with concomitant alcoholism.

Clinical quality, and withdrawal in a long-term care setting. patients with a history of chronic

Pharmacology symptoms as main alcohol abuse. Limitations included:

outcomes.  One year after study termination, 46%  Small number of included

2002;57(11):759-764. of the successful participants were still patients.

off regular BZ use.  Potentially confounding effect

of the unequal dropout rate in

both treatment groups.

 Study was not performed in a

long-term care setting.



37 Habraken et al. To describe and assess:  Study type: Randomized, double-  34% of subjects dropped out before Gradual withdrawal from BZs is

 The long-term effect of blind, placebo- controlled clinical trial the end of the study. possible in residents of homes for

“Gradual withdrawal gradual withdrawal .  In the placebo group, the level of daily the elderly, and that it can have a

from benzodiazepines from BZs on the daily  Setting: 10 homes for the elderly in functioning showed a mean positive effect on their daily

in residents of homes functioning of residents Ghent. improvement of 4 points at 6 months functioning. No major withdrawal

for the elderly: of homes for the  Study population: compared to baseline, and of 1.6 symptoms were observed, although

Experience and elderly.  Size: N = 55. points at 1 year compared to baseline. there was a decrease in sleep

suggestions for future  81.8% Female.  In the lorazepam group, a deterioration quality during withdrawal.

research”  Mean age 84 years. of 4.2 points and 6 points was found at

6 months and 1 year, respectively. Limitations included:

European Journal of  The ANOVA for repeated  Small sample size due to high

Clinical measurements of the level of daily dropout rate.

Pharmacology functioning showed a significant group  Selective cooperation of

effect (p = 0.02), a significant time residents.

1997;51(5):355-358. effect (p = 0.03), and no interaction

effect (p = 0.74).

 The subjective sleep quality decreased

in the placebo group compared to

baseline, while it increased in the

lorazepam group.









25

Table 2: Detailed Description of Review and Descriptive/Informational Articles



# Article Objectives Study Design Main Findings Discussion

1 Doraiswamy To describe and assess:  Study type:  Recognition and treatment of anxiety and The newer antidepressants

 The presentation and Descriptive/Informational depression will likely gain more attention in the next can decrease symptoms,

“Contemporary management of article. 30 to 50 years because of the projected growth of improve quality of life, and

management of comorbid anxiety and the geriatric population. potentially promote healthier

comorbid anxiety and depression in elderly  The most common presentation of anxiety in elderly outcomes in geriatric patients

depression in geriatric individuals. patients is comorbid anxiety and depression. who have comorbid anxiety

patients”  Although age is not a risk factor for either anxiety or and depression and/or

depression, factors associate with aging are comorbid mental and physical

Journal of Clinical substantial risk factors for development of these illness.

Psychiatry conditions.

 There is a close association in older people between

2001;62(Suppl 12):30- untreated mental illness and exacerbation of

35. physical illness.

 Some of the newer antidepressants are more

appropriate long-term options for the treatment of

comorbid anxiety and depression than either BZs or

tricyclic antidepressants.





2 Kogan et al. To describe and assess:  Study type:  The age-related decline in prevalence of anxiety Assessment of anxiety in

 The issues to consider Descriptive/Informational disorders must be interpreted with caution. older adults is in its infancy.

“Assessment of anxiety in assessing anxiety in article.  Clinicians must realize that the presentation of The limitations of the anxiety

in older adults: Current older adults. anxiety in older adults is not necessarily the same assessment literature with

status” as it is in younger adults. older adults creates a

 There are many factors that must be considered dilemma for practicing

Journal of Anxiety when assessing anxiety in older adults. clinicians who desire a means

Disorders  More evidence is needed on the psychometric to assess anxiety in this

properties of self-report instruments and clinician- population. Clinicians must

2000;14(2):109-132. rated instruments for the assessment of anxiety in consider the strengths and

older adult populations. weaknesses of the

instruments that are available

and choose measures

cautiously.









26

Table 2: Detailed Description of Review and Descriptive/Informational Articles



# Article Objectives Study Design Main Findings Discussion

3 Sadavoy et al. To provide:  Study type: Review  Anxiety disorders and symptoms are a common Anxiety disorders and

 A current review and article. presenting problem in the elderly. symptoms in old age,

“Treatment of anxiety synthesis of the present  Data sources: Medline,  Current knowledge and research findings are although common, have

disorders in late life” state of knowledge of references in key limited. received little research focus

anxiety disorders and textbook articles and  Extrapolation from adult studies are of use, but to date. A comprehensive,

Canadian Journal of symptoms in the elderly. other papers, and clinical important limitations are evident because of the careful approach by the

Psychiatry empirical knowledge and nature, uniqueness, and complexity of the geriatric clinician to assessment and

experience of the psychiatry patient. management is required

1997;42(Suppl 1):28S- authors.  Comorbidity, especially with depression, medical because anxiety is often a

34S. conditions, drugs, and dementia, remains an comorbid condition in the

important concept in assessment and approach to elderly. Effective treatments

management of anxiety in the older person. are available and should be

 Comprehensive assessment of anxiety symptoms applied in a flexible,

requires consideration of physical, intellectual, integrated, and specific

environmental, and social determinants. manner.

 Major anxiety disorders, as defined by DSM-IV, and

anxiety symptoms are significant problems in the

older adult population and are responsible for

significant morbidity and cost to the health care

network.





4 Verma et al. To describe and assess:  Study type:  Psychiatric disorders in long-term care facilities Agitation can occur as a

 Some of the causes and Descriptive/Informational remain underdiagnosed and inappropriately or result of psychiatric and

“Management of the interventions that can article. inadequately treated. nonpsychiatric conditions,

agitated elderly patient assist physicians caring  Disruptive behavior should not always be assumed and appropriate treatment

in the nursing home: for the agitated elderly to have a psychiatric etiology. needs to be directed at the

The role of the atypical in long-term care  Description of different treatment strategies is target symptoms.

antipsychotics” settings. presented.



Journal of Clinical

Psychiatry



1998;59(Suppl 19):50-

55.









27

Table 2: Detailed Description of Review and Descriptive/Informational Articles



# Article Objectives Study Design Main Findings Discussion

5 Furniss et al. To describe and assess:  Study type: Review  Nursing home residents are prescribed more drugs The research reviewed

 Medication use in article. than their counterparts living at home. highlighted the over-

“Medication use in elderly nursing home  Data sources: Medline,  Iatrogenic disease is high in the elderly and is prescribing of medication and

nursing homes for residents with specific Excerpta Medica, important in nursing home residents because they the potential for the

elderly people” reference to International are prescribed more drugs and have greater rationalization of prescription

psychotropics and aims Pharmaceutical Abstracts physical and mental illness. medication regimes in nursing

International Journal of to raise awareness of (IPA), and Pharmline.  Nursing home residents are often taking home residents.

Geriatric Psychiatry the issue.  Keywords included: inappropriate medication.

nursing home(s), drug  Psychotropic drugs are often prescribed to nursing

1998;13:433-439. therapy, or drugs. home residents and laws have been passed in the

 239 studies were USA to limit the use of neuroleptics with good effect.

reviewed.  By law, pharmacists play an active role in

medication management in nursing homes in the

USA and have been shown to be cost-effective.

 Small studies in the UK have shown pharmacists to

be of potential benefit.



6 Palmer et al. To describe and assess:  Study type:  Anxiety disorders are underdiagnosed in late life. Although it has commonly

 The factors which may Descriptive/Informational  A common problem in the literature is the application been thought that anxiety

“Anxiety disorders in the lead to under- or mis- article. of DSM-IV-like criteria developed from studies of disorders are less common in

elderly: DSM-IV and diagnosis of anxiety younger adults to geriatric samples without regard the elderly, there are several

other barriers to disorders in the elderly, for atypical symptom presentations, high occurrence reasons to question the data

diagnosis and and impede of depressive and medical comorbidity, and on which such assertions are

treatment” identification of influence of aging-related psychosocial changes on based. Further research is

appropriate treatment. the clinical picture. needed to determine the

Journal of Affective  Diagnostic problems are further compounded by degree to which DSM-IV

Disorders therapeutic ones. criteria for specific anxiety

 Clinicians are often forced to make treatment disorders need modification

1997;46:183-190. decisions for their elderly patients based on to better describe the typical

uncontrolled clinical observations or questionable patterns of clinically

extrapolation of treatment data in younger adults. significant anxiety in the

elderly.



The authors comment that

more research needs to be

conducted in geriatric

psychiatry to fill the existing

gaps.









28

Table 2: Detailed Description of Review and Descriptive/Informational Articles



# Article Objectives Study Design Main Findings Discussion

8 Schneider To describe and assess:  Study type:  Situational and pathological anxiety are common in This review of the

 The issues involved with Descriptive/Informational the elderly. epidemiology, characteristics

“Overview of diagnosing and treating article.  There is significant comorbidity between anxiety and of anxiety in late-life, patterns

Generalized Anxiety late-life anxiety. depression in the elderly. of medication use, and

Disorder in the Elderly”  Differential diagnosis involves both distinguishing treatment of anxiety disorders

anxiety disorders from other medical and psychiatric in the elderly shows the

Journal of Clinical disorders and distinguishing among the various importance of proper

Psychiatry anxiety disorders. diagnosis and treatment to

 Pharmacological treatments used to treaty various achieve desirable outcomes

1996;57(Suppl 7):34-45. anxiety disorders include benzodiazepines, in the management of anxiety

buspirone, tricyclics, MAOIs, and SSRIs. in elderly individuals.

11 Heffern To describe and assess:  Study type:  There are benefits and risks associated with the use The authors commented that

 The Descriptive/Informational of electroconvulsive therapy for the treatment of this review highlights the

“Psychopharmacological pharmacotherapeutics article. depression and/or anxiety. importance of using empirical

and electroconvulsive of antianxiety and  Other treatment options are discussed, such as knowledge, increased

treatment of anxiety and antidepressant pharmaceutical treatment and cognitive-behavioral autonomy and accountability,

depression in the medication in the therapy. and increased collaboration

elderly” elderly. with other health care

 The benefits and risks clinicians to make significant

Journal of Psychiatric of electroconvulsive improvements and advances

and Mental Health therapy (ECT). in psychiatric patient care.

Nursing



2000;7:199-204.

13 Gurvich et al. To describe and assess:  Study type:  The Omnibus Budget Reconciliation Act (OBRA) of Psychotropic medications are

 The appropriateness of Descriptive/Informational 1987 limited the use of psychotropic medications in sometimes required to

“Appropriate use of psychotropic drug use in article. residents of long-term care facilities. maximize quality of life and

psychotropic drugs in nursing homes.  Updates of OBRA guidelines have liberalized some functional status in nursing

nursing homes” dosing restrictions, but documentation of necessity home residents. In tailoring

and periodic trials of medication withdrawal are still pharmacologic regimens for

American Family emphasized. these patients, physicians

Physician  Antidepressants are typically underutilized and need to give careful attention

antipsychotics and BZs have been used to accurate diagnosis,

2000;61:1437-1446. excessively. appropriate dosing, side

 Tricyclics have many side effects and are not effects, drug interactions, and

preferred treatment options. pertinent drug

 Anxiety and insomnia are common problems. pharmacokinetics.

 Antipsychotics should only be used for specific Reassessment at regular

diagnoses. intervals is necessary.









29


Related docs
Other docs by HC11112907480
SL 25142 REV01 R05 09
Views: 1  |  Downloads: 0
ortakd
Views: 3  |  Downloads: 0
OCR Document
Views: 0  |  Downloads: 0
Chapter 28
Views: 0  |  Downloads: 0
natchiappanreport
Views: 0  |  Downloads: 0
Rapport
Views: 54  |  Downloads: 0
ati oct 2011
Views: 2  |  Downloads: 0
Transistor F06
Views: 1  |  Downloads: 0
101007 crm teleconference
Views: 0  |  Downloads: 0
By registering with docstoc.com you agree to our
privacy policy

You are almost ready to download!

You are almost ready to download!